Can naltrexone be used as an off‑label adjunct for a patient with obsessive‑compulsive disorder who has failed an adequate trial of a selective serotonin reuptake inhibitor and exposure‑response prevention cognitive‑behavioral therapy, especially if they also have comorbid impulsive or reward‑seeking behaviors?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Naltrexone for OCD: Not Recommended

Naltrexone should not be used as an adjunct treatment for obsessive-compulsive disorder, even in treatment-resistant cases with comorbid impulsive behaviors. The evidence-based augmentation strategies for SSRI-resistant OCD are antipsychotics (risperidone, aripiprazole), clomipramine, and glutamatergic agents (N-acetylcysteine, memantine)—not naltrexone 1.

Why Naltrexone Is Not Appropriate

Lack of Guideline Support

The comprehensive 2019 Nature Reviews Disease Primers guideline on OCD treatment explicitly outlines evidence-based augmentation strategies for treatment-resistant OCD 1. Naltrexone is conspicuously absent from these recommendations. The guideline specifies:

  • First-tier augmentation: Antipsychotics (risperidone, aripiprazole) with documented efficacy, though only one-third of SSRI-resistant patients show clinically meaningful response
  • Second-tier augmentation: Clomipramine (with careful monitoring for drug interactions, seizures, arrhythmias, and serotonin syndrome)
  • Emerging options: Glutamatergic agents like N-acetylcysteine (strongest evidence with 3 of 5 RCTs positive) and memantine

FDA Label Limitations

The FDA-approved indications for naltrexone are alcohol use disorder and opioid dependence 2. There is no mention of OCD or obsessive-compulsive symptoms in the approved uses. The clinical trials demonstrating naltrexone efficacy specifically excluded patients with "psychosis, dementia, and secondary psychiatric diagnoses" 2, which would encompass many OCD patients with comorbidities.

Negative Research Evidence

The single controlled trial of naltrexone augmentation in OCD showed no benefit and potential harm 3. This 2008 double-blind, placebo-controlled crossover study of 10 SSRI-resistant OCD patients found:

  • No significant effect on Y-BOCS scores (the primary OCD symptom measure)
  • Significantly higher scores on CGI, MADRS, and HAM-A compared to placebo, indicating worsening of global functioning, depression, and anxiety
  • The authors concluded naltrexone may cause "non-specific exacerbation on anxiety and depression"

The Impulsivity Caveat Does Not Apply

While the expanded question mentions comorbid impulsive or reward-seeking behaviors, this does not justify naltrexone use for several reasons:

Different Phenomenology

The research evidence for naltrexone involves compulsive sexual behavior 4, 5, 6, not OCD. These are distinct conditions:

  • Compulsive sexual behavior involves reward-seeking, pleasure-driven urges that naltrexone may attenuate through opioid receptor blockade
  • OCD compulsions are anxiety-driven, ego-dystonic behaviors performed to reduce distress—not for pleasure or reward

The 2019 guideline explicitly distinguishes OCD from impulse control disorders and addictive behaviors 1.

Evidence Is for Different Conditions

The positive naltrexone studies cited involve:

  • Compulsive sexual behavior 4, 5, 6
  • Pica and trichotillomania 7
  • Ketamine use disorder 8

None of these conditions are OCD, and the mechanisms differ fundamentally. The one study that actually tested naltrexone in OCD patients was negative 3.

Recommended Treatment Algorithm for SSRI + ERP Failures

When a patient has failed adequate SSRI trial (8-12 weeks at high dose) plus exposure-response prevention therapy 1:

Step 1: Optimize Current Treatment

  • Ensure SSRI dose is truly adequate (higher than depression doses: sertraline 200mg, fluoxetine 60-80mg, escitalopram 20-30mg)
  • Verify ERP was delivered by trained therapist with adequate homework compliance (20+ hours minimum)
  • Extend SSRI trial to 6 months if partial response

Step 2: Switch Strategies

  • Trial a different SSRI at high dose
  • Consider clomipramine 150-250mg (if no prior trial)
  • Trial SNRI (venlafaxine 225-375mg)

Step 3: Evidence-Based Augmentation

In order of evidence strength:

  1. Antipsychotic augmentation (risperidone 1-3mg or aripiprazole 10-20mg) - most commonly used, but monitor closely for metabolic effects 1

  2. N-acetylcysteine augmentation (1200-2400mg/day) - best evidence among glutamatergic agents, three positive RCTs 1

  3. Memantine augmentation (10-20mg/day) - several positive trials in SSRI-resistant OCD 1

  4. Clomipramine + SSRI combination - effective but requires careful monitoring for seizures, arrhythmias, serotonin syndrome due to drug-drug interactions 1

Step 4: Intensive CBT

If standard ERP failed, consider intensive CBT protocols (multiple daily sessions over days to weeks) 1

Critical Pitfalls to Avoid

  • Do not use naltrexone based on superficial behavioral similarities between OCD and addiction—the underlying neurobiology differs
  • Do not assume "impulsive features" in OCD justify addiction medications—true OCD compulsions are anxiety-reducing, not reward-seeking
  • Do not extrapolate from compulsive sexual behavior studies to OCD—these are separate diagnostic entities with different treatment responses
  • Monitor carefully with antipsychotic augmentation for weight gain and metabolic syndrome, as effect sizes are modest (only 1 in 3 respond) 1

References

1
Guideline

obsessive-compulsive disorder.

Nature Reviews Disease Primers, 2019

3
Research

Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2008

5
Research

Augmentation with naltrexone to treat compulsive sexual behavior: a case series.

Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2010

Related Questions

Is naltrexone appropriate for treating compulsive pornography use in an adult, and what dosing and monitoring are recommended?
What is the indication for naltrexone (opioid receptor antagonist) in an adult patient with a confirmed diagnosis of porn addiction who has failed other treatments such as cognitive-behavioral therapy?
Does naltrexone (Naltrexone) decrease libido?
Are there any off‑label uses for naltrexone?
What is the best treatment for obsessive‑compulsive disorder in a patient who cannot tolerate selective serotonin reuptake inhibitors (SSRIs)?
Has the Lone Star tick always contained the alpha‑gal carbohydrate in its saliva?
In patients taking nitrofurantoin who develop severe diarrhea, how long after completing the antibiotic course should the diarrhea resolve?
Should I increase fluoxetine (Prozac) from 20 mg daily to 40 mg daily, or first increase to 30 mg?
Can I give Wegovy (semaglutide) to a 16-year-old who is overweight but not obese for a two-month course?
Can a patient who had an ultrasound two months ago undergo a repeat ultrasound if her pain remains unchanged?
After reverse total shoulder arthroplasty, what is the most common orientation of dislocation (anterior versus posterior)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.